叶酸受体 4 表达的 T 细胞与食管鳞状细胞癌患者的无病生存相关。
Folate Receptor 4-Expressing T cell Is Associated with Disease-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.
机构信息
Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Hebei Medical University, Shijiazhuang 050017, China.
出版信息
Dis Markers. 2022 Jun 15;2022:4351949. doi: 10.1155/2022/4351949. eCollection 2022.
BACKGROUND
Folic acid receptor 4 (FR4) significantly downregulates the expression of regular T cells (Treg) and improves the effect of chemotherapy and PD-1/PD-L1 inhibitors. However, the FR4 expression in squamous cell carcinoma (ESCC) remains unclear.
METHODS
Patients with primary ESCC who visited our hospital between 1 February 2012 and 30 September 2016 were enrolled in this study. FR4 expressions in ESCC patients were detected by immunohistochemistry staining, and the association with clinical characteristics and the overall survival (OS) or disease-free survival (DFS) was analyzed.
RESULTS
One hundred and forty-eight qualified cases of ESCC patients were retrieved, including 34 females. Ninety-four cases had lymph node metastasis (63.51%), 104 patients received adjuvant therapy (70.27%), and the rate of FR4 positive was 67.57% (100/148). Among FR4 positive patients, 75 cases received adjuvant therapy, and patients who received chemotherapy were significantly better than that of patients who did not receive chemotherapy. In patients with FR4 negative expression, 48 cases received adjuvant therapy, which was significantly worse than that of patients who did not receive chemotherapy.
CONCLUSIONS
Postoperative adjuvant chemotherapy prolonged the survival in FR4 positive ESCC patients, whereas adjuvant therapy in patients with FR4 negative needs to be further improved.
背景
叶酸受体 4（FR4）显著下调常规 T 细胞（Treg）的表达，提高化疗和 PD-1/PD-L1 抑制剂的疗效。然而，鳞状细胞癌（ESCC）中 FR4 的表达尚不清楚。
方法
本研究纳入了 2012 年 2 月 1 日至 2016 年 9 月 30 日期间在我院就诊的原发性 ESCC 患者。采用免疫组织化学染色法检测 ESCC 患者 FR4 的表达，并分析其与临床特征及总生存（OS）或无病生存（DFS）的关系。
结果
共纳入 148 例符合条件的 ESCC 患者，其中女性 34 例。94 例患者有淋巴结转移（63.51%），104 例患者接受了辅助治疗（70.27%），FR4 阳性率为 67.57%（100/148）。在 FR4 阳性患者中，75 例接受了辅助化疗，化疗组患者的生存情况明显优于未化疗组。在 FR4 阴性表达的患者中，48 例接受了辅助治疗，其生存情况明显差于未化疗组。
结论
术后辅助化疗延长了 FR4 阳性 ESCC 患者的生存时间，而 FR4 阴性患者的辅助治疗需要进一步改善。
Zotero 插件